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Abst rac t
Introduction: Approximately 15% of appropriately treated patients with early syphilis remain serofast. The patho-
genesis and clinical significance of this phenomenon are unclear. 
Aim: To determine the significance of Treponema pallidum-specific immune responses and autoimmunity in the 
treatment outcome of syphilis (serofast or proper serological response). 
Material and methods: Forty-eight patients with secondary and early latent syphilis (ELS) were enrolled in this 
study. Reactivity of IgM/IgG antibodies to the treponemal antigens TpN47, TpN17, TpN15 and TmpA was evaluated 
before and 12 months after intramuscular penicillin therapy for syphilis. Additionally, the presence of antinuclear 
antibodies (ANA) was determined 12 months after treatment. 
Results: After 1 year, patients were stratified into two groups based on their serological response: (1) serofast (n = 10) 
and (2) serologically-cured (n = 38) patients. The serological cure rate was 79.2% at 12 months after treatment. Weak 
pre- and post-treatment antibody reactivity to TpN47 antigen was found to be significantly associated with a higher 
risk of the serofast state (OR = 64; 95% CI: 5.01–817; p < 0.005). Patients who remained serofast had a significantly 
higher ANA prevalence and mean titer when compared to those with proper serological responses (100% vs. 5.3%, 
respectively, p < 0.005; 1 : 640 vs. 1 : 160, respectively, p < 0.005). 
Conclusions: We demonstrate that baseline antigen-specific immune response to Treponema pallidum may be an 
important predictor of the treatment outcome. Further studies are warranted to identify the role of autoimmunity 
in the pathomechanism of the serofast state. 
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Introduction
Parenteral penicillin is the therapy of choice at ev-
ery stage of syphilis, but due to inability to culture Trepo-
nema pallidum in vitro, monitoring of treatment effi-
cacy relies almost entirely on the measurement of the 
immune response (i.e. serological assays) rather than 
direct T. pallidum tests. Appropriate serologic response 
in syphilis has been defined by Centers for Disease Con-
trol and Prevention (CDC) as a four-fold or greater decline 
in the titer of non-treponemal assays when performed 
6 months after beginning of the treatment [1]. However, ap-
proximately 15% of patients with early syphilis do not fol-
low the classical patterns of serological response to therapy, 
exhibiting less than a four-fold decline in non-treponemal ti-
ters without evidence of treatment failure or reinfection [2].
Until now, only a limited number of studies have been 
conducted to investigate serological responses after syphi-
lis treatment. In these studies, several factors have been 
implicated as predictors of improper serological response 
to treatment, such as older age of patients, lower baseline 
non-treponemal antibody titers and lack of appearance of 
Jarisch-Herxheimer reaction [3–5]. These studies, however, 
did not establish the clinical and biological explanation for 
the serofast state. The absence of novel methods to con-
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firm eradication of T. pallidum leads to uncertainty regard-
ing whether ‘serofast state syphilis’ is a signature of a per-
sistent infection or simply a residual immune response in 
the absence of the viable pathogen. Thus, a majority of 
serofast patients undergo additional treatment despite 
lack of any evidence to support this practice. 
Aim
To better understand and investigate the serofast 
condition, we analyzed an antigen-specific immune re-
sponse that occurs during the infection and after the 
therapy. Since non-treponemal antibodies were identi-
fied as autoreactive particles [6], the second aim of the 
current study was to demonstrate a presumptive link 
between infection with T. pallidum and autoimmunity. 
Material and methods
Patients and study design
Secondary and early latent syphilis (ELS) patients 
(n = 50) in their first episode of disease were enrolled at 
the Department of Dermatology of the Jagiellonian Uni-
versity Medical College in Krakow, Poland between 2015 
and 2017. All patients included in the study were positive 
both for non-treponemal and treponemal tests at enroll-
ment. Syphilis clinical staging was determined by a board-
certified dermatologist using the Centers for Disease Con-
trol and Prevention (CDC) criteria [1]. After blood sampling 
for laboratory tests, including treponemal-specific tests 
(INNO-LIA Syphilis Score Assay), patients were admin-
istered intramuscular benzathine penicillin (2.4 million 
units). All study subjects were tested for concurrent HIV 
infection. Antiretroviral therapy was introduced in all pa-
tients with confirmed HIV co-infection. All cases of HIV in-
fection were detected at enrollment, as none of the study 
patients were aware of their HIV status. After completion 
of the treatment, patients returned every 3 months for 
follow-up assessment (including non-treponemal test-
ing; rapid plasma regain assay – RPR). Six months after 
completing the treatment, serological responses were as-
sessed. The data indicated that 14 of 50 individuals did 
not achieve proper serological response, defined as at 
least a four-fold decline in RPR titer when compared to 
the pre-treatment values. In all of the subjects, cerebro-
spinal fluid (CSF) examination was performed. Diagnosis 
of neurosyphilis was determined according to CDC guide-
lines (i.e. reactive CSF VDRL or CSF pleocytosis of ≥ 5/μl 
and CSF protein concentration ≥ 45 mg/dl). In 2 cases, as-
ymptomatic neurosyphilis was confirmed and these pa-
tients were excluded from further analysis. Re-treatment 
with intramuscular benzathine penicillin (2.4 million units) 
was administered in the remaining 12 patients. Twelve 
months after treatment, two of these twelve  individuals 
achieved proper serological response. All patients stud-
ied were classified as (1) the serofast state group (n = 10) 
defined as the failure of the RPR titer to show a four-fold 
decline between the baseline and the 12-month visit and 
(2) the serologically-cured group (n = 38) defined as at 
least a four-fold decline in the RPR titer in comparison to 
the pre-treatment RPR results. Twelve months after treat-
ment, in all the remaining individuals, serum samples for 
INNO-LIA Syphilis Score testing and antinuclear antibodies 
(ANAs) were collected. The study was approved by the Jagi-
ellonian University Bioethics Committee (approval number 
KBET/164/B) and written informed consent was obtained 
from all participants. 
Laboratory measurements
The RPR assay (Becton Dickinson & Company, Sparks, 
MD, USA) and the INNO-LIA Syphilis Score Assay (Fujire-
bio Europe N.V., Gent, Belgium) were performed accord-
ing to the manufacturer’s instructions. The INNO-LIA 
Syphilis Score Assay detects IgM/IgG antibodies spe-
cific for treponemal antigens TpN47 (47 kDa), TpN17 
(17 kDa), TpN15 (15 kDa) and TmpA (42 kDa) (pool of re-
combinant antigens). The interpretation of the results 
was performed according to the instructions provided 
by the manufacturer. Briefly, a rating from 0 to 3+ was 
given to the antigen lines (bands) on the developed strips 
by comparing their intensities with those of the control 
lines. Weak, moderate and strong intensity corresponded 
with the 1+, 2+ and 3+ ratings, respectively. 
ANA was detected by indirect immunofluorescence 
on HEp-2 cells. The assessment of autoantibody titers 
and five main patterns (granular, homogenous, nucleo-
lar, centromere and other patterns) were carried out with 
a semi-automated system (AKLIDES®; Medipan GmbH, 
Dahlewitz, Germany) and confirmed by visual observa-
tion. Sera assessed as positive (titer ≥ 1 : 160) were fur-
ther analyzed by specific second-step autoantibody as-
says according to the staining pattern. The selection of 
the confirmatory assays was carried out according to test 
algorithms of routine diagnostics. 
Statistical analysis
Statistical analysis was carried out using Statistica 7.1 
PL software (TIBCO Software Inc. Palo Alto, CA). Unless 
stated otherwise, data were expressed as median and 
minimum-maximum values. Continuous variables were 
compared with the Mann-Whitney U test. The c2 test 
or the Fisher’s exact test was used for the dichotomous 
variables. Correlations were assessed using linear regres-
sion analysis (Pearson). A p-value < 0.05 was considered 
statistically significant. 
Results
Patient characteristics
We enrolled 50 patients with the first episode of early 
syphilis, who were staged as secondary syphilis (50%) or 
Advances in Dermatology and Allergology 5, October / 2019622
Maciej Pastuszczak, Agnieszka Kotnis-Gąska, Bernadetta Jakubowicz, Anna Wojas-Pelc
ELS (50%). Newly diagnosed HIV co-infection was found 
in ten individuals (20%). Six months after completing 
syphilis treatment, 14 (28%) patients did not achieve an 
at least four-fold decline in RPR titer. In 2 of them (14.3%), 
asymptomatic neurosyphilis was confirmed, what may 
explain the improper serological response. These 2 pa-
tients were excluded from further follow-up. All 12 re-
maining patients were retreated with intramuscular 
benzathine penicillin (2.4 million units). Six months after 
retreatment, only 2 (16.7%) individuals demonstrated 
a decrease in the RPR titer and met the criteria of proper 
serological response (i.e. at least four-fold decline in RPR 
titer in comparison to pre-treatment RPR results).
Twelve months after completing the syphilis treat-
ment, the patients were stratified into: (1) the serofast 
state group (n = 10), and (2) the serologically-cured group 
(n = 38). Patients from the serofast state group had 
a lower baseline RPR titer when compared to individuals 
from the serologically-cured group. The groups did not 
differ with respect to sex, age, clinical stage of syphilis 
and frequency of concomitant HIV infection (Table 1).
 Serum antibody reactivity to protein antigens 
of T. pallidum before and after syphilis treatment
All analyzed antigens (i.e. TpN47, TpN17, TpN15 and 
TmpA) were present in all syphilitic patients before treat-
ment. In most individuals, pre-treatment intensity of the 
reaction for TpN17, TpN15 and TmpA was assessed as 
moderate or strong (i.e. 2+ or 3+). In contrast, diverse 
intensities of bands were observed for TpN47. Among all 
studied patients, a comparable number of patients with 
weak, moderate and strong reactivity for TpN47 were 
found (Figure 1 A). 
In all patients, antibodies to the full complement of 
treponemal antigens were still demonstrable 1 year after 
treatment. The antibody reactivity to the antigens had 
not changed in comparison to the pre-treatment results 
(Figure 1 B). 
Table 1. Characteristics of patients from the serofast state and serologically-cured groups
Parameter Serofast state group
(n = 10)
Serologically-cured group
(n = 38)
P-value
Sex, males, n (%) 8 (80) 37 (97.4) NS
Age [years] 32 (20–41) 33 (19–39) NS
HIV co-infection, n (%) 2 (20) 7 (18.4) NS
Clinical stage of syphilis, n (%): NS
Secondary 5 (50) 22 (57.9)
Early latent 5 (50) 14 (42.1)
Baseline RPR titer 16 (4–512) 64 (8–256) NS
HIV – human immunodeficiency virus, RPR – rapid plasma regain, NS – not significant. The values are presented as medians (min.-max. range) if not otherwise 
stated. 
Figure 1. A – Percentages of patients with pre-treatment positive rates for specific anti-treponemal antibodies (TpN47, 
TpN17, TpN15, TmpA) stratified according to the reaction intensity (0, 1+, 2+, 3+). B – Percentages of patients with post-
treatment positive rates for specific anti-treponemal antibodies (TpN47, TpN17, TpN15, TmpA) stratified according to the 
reaction intensity (0, 1+, 2+, 3+)
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 Serum antibody reactivity to protein antigens  
of T. pallidum among the serofast state  
and serologically-cured groups
The percentage of patients with weak pre-treatment an-
tibody reactivity to TpN47 (i.e. 1+) was significantly higher in 
the serofast state group when compared to those from the 
serologically-cured group (p < 0.005, Table 2). Weak (i.e. 1+) 
pre-treatment antibody reactivity to TpN47 was significantly 
associated with a higher risk of the serofast state (OR = 64; 
95% CI: 5.01–817, p < 0.05). There were no differences in 
the analyzed groups in intensity of the reaction for TpN17, 
TpN15 and TmpA (Table 2). Similar results were found for 
post-treatment antibody reactivity to the profile of the ana-
lyzed treponemal antigens (data not shown). 
 ANA prevalence rates among serofast state  
and serologically-cured patients 
All patients with the serofast state had positive ANA 
(i.e. titer ≥ 1 : 160). In comparison, the proportion of sero-
logically-cured individuals with positive ANA was only 5.3% 
(p < 0.05). Interestingly, the mean ANA titer in the serofast 
state group was significantly higher when compared to 
those who had a proper serological response (1 : 640 and 
1 : 160, respectively; p < 0.05). The most frequent ANA 
staining patterns were granular, followed by homogenous. 
In all cases, further confirmatory testing revealed that 
these anti-nuclear antibodies were non-specific. 
Discussion
In the present study, the proportion of patients who 
had a serological non-response 6 months after treat-
ment was 25%. This proportion decreased to 20.8% at 
12 months after therapy. This value varies widely among 
other studies, and ranges from 9.4% to 44.4% [2]. Such 
a broad range can be explained in part by the variable 
proportion of different stages of syphilis among patients 
included in these studies and by an inconsistent definition 
of serological non-response. Noteworthy, we defined the 
serofast state to be lack of at least a four-fold decline in 
RPR titer after syphilis treatment. Some previous studies 
have found an association of serological outcomes with 
the stage of syphilis [7, 8]. In all of them, there was an 
increased likelihood of the serofast state among patients 
with ELS compared to those with the primary and second-
ary stage of the disease. The high proportion of serological 
non-responders observed in our study can be explained by 
the fact that 50% of patients included had ELS. 
Some recent studies included lumbar punctures per-
formed among individuals with serological non-response 
to syphilis therapy [9–11]. The proportion of patients who 
had reactive CSF suggestive of neurosyphilis among 
these studies varied from 5.7% to 34.6%. Such differ-
ences can be partially explained by the different criteria 
of neurosyphilis that were applied. Moreover, in some of 
these studies, patients were initially treated for syphilis 
with regimens that have not been proven to be effec-
tive in syphilis treatment, such as minocycline [9]. We 
performed CSF examination in all serofast state patients 
at 6 months after penicillin therapy and identified 2 out 
of 14 (14.3%) individuals who met the criteria for neu-
rosyphilis. Our data suggest that neurosyphilis may be 
detected in patients despite the appropriate therapy for 
early-stage syphilis. Thus, clinicians should be aware of 
Table 2. Characteristics of pre-treatment specific treponemal antibody reactivity and ANAs positivity among individuals 
from the serofast state and serologically-cured groups
Parameter Serofast state group
(n = 10)
Serologically-cured group
(n = 38)
P-value
Baseline TpN47, n (%): 0.0001
1+ 7 (70) 2 (5.3)
≥ 2+ 3 (30) 36 (94.7)
Baseline TpN17, n (%): NS
1+ 0 (0) 2 (5.3)
≥ 2+ 10 (100) 36 (94.7)
Baseline TpN15, n (%): NS
1+ 0 (0) 2 (5.3)
≥ 2+ 10 (100) 36 (94.7)
Baseline TmpA, n (%): NS
1+ 4 (40) 12 (31.6)
≥ 2+ 6 (60) 26 (68.4)
Post-treatment ANAs positivity, n (%) 10 (100) 2 (5.3) 0.0001
ANA titer 1 : 640 (1 : 160–1 : 2560) 1 : 160 0.005
ANA – anti-nuclear antibodies, NS – not significant. The values are presented as medians (min.–max. range) if not otherwise stated.
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these findings. Careful follow-up until proper serological 
response occurs is strongly recommended and the CSF 
examination in patients who remain serofast should be 
considered. 
In previous studies, it was observed that sera sam-
ples of syphilitic patients showed reactivity against pro-
teins TpN47, TpN17, TpN15 and TmpA, and that as the 
infection progressed, reactivity to all antigens increased 
[12–14]. Our results correspond well with those reported 
in previous studies. In the current study, patients with 
secondary syphilis and ELS had moderate or strong pre-
treatment reactivity against the TpN17, TpN15 and TmpA 
antigens. It was previously shown that the TpN47 band 
is present in all phases of syphilis [14, 15]. Interestingly 
however, in early syphilis, the intensity of the reaction 
to TpN47 is more intense than in late syphilis, and can 
even become negative in later stages of the infection. 
Of note, we observed a significantly greater variation in 
staining intensity for TpN47 compared to the other an-
tigens examined. The reactivity to TpN47 was assessed 
as weak, moderate or strong in 34%, 39% and 26% of 
all patients, respectively. Further analysis showed that 
the weak pre-treatment reactivity to TpN47 antigen was 
associated with a significantly higher risk of improper 
serological response at 12 months after completing the 
syphilis therapy. The mechanism underlying this observa-
tion remains unclear. 
It has recently been suggested that a robust host 
pro-inflammatory immune response to the treponemal 
infection, occurring shortly after initiation of the treat-
ment, is associated with a lower risk of maintaining the 
serofast state [16]. Thus, presumably, individuals with 
weak reactivity to TpN47 may have a down-regulated im-
mune response, which results in an improper serological 
response. Further studies are needed in order to confirm 
this observation. We can only speculate that this down-
regulation may be associated either with host genetic 
factors, such as single nucleotide polymorphisms affect-
ing immune response to T. pallidum, or with an infection 
caused by less immunogenic treponemal strains. 
Treponemal antibodies have been shown to persist in 
syphilis patients after therapy, indicating the presence of 
immune cells that continue to produce T. pallidum specif-
ic antibodies. Our results are consistent with those from 
the previous studies devoted to describing treponemal 
antigens in sera from treated patients [13, 14]. Twelve 
months after therapy we detected treponemal antibodies 
against all analyzed molecules (i.e. TpN47, TpN17, TpN15 
and TmpA) even though the RPR titer had declined signif-
icantly or even reverted to be nonreactive. Interestingly, 
the band intensity remained almost unchanged. These 
and previous results suggest that methods for detecting 
treponemal antibodies may not be valuable for monitor-
ing syphilis treatment. 
In all patients with the serofast state, we found the 
presence of anti-nuclear antibodies (ANA) at a titer of 
1 : 160 or above. In all these cases, confirmatory test-
ing revealed that the ANA were not antigen specific. In-
terestingly, among individuals with a proper serological 
response there were only two cases with a positive ANA 
test. The ANA titer in all of these patients was low. Of 
note, none of individuals with ANA had complained of 
any symptoms characteristic of autoimmune disorders. 
The basis of this seropositivity in patients with a serofast 
state is puzzling. Nontreponemal antibodies are autore-
active since cardiolipin, the main antigenic component 
that binds to these antibodies, is present in mitochon-
drial membranes [6]. Thus, one of the explanations may 
be that this persistent presence of the nontreponemal 
antibodies in serofast patients leads to the destruction of 
host tissues and leads to production of ANAs. The ques-
tion of why in some patients, this excessive production 
of nontreponemal antibodies occurs and whether persis-
tence of nontreponemal antibodies after effective ther-
apy represents failure of the immune system tolerance 
or lack of the pathogen clearance, remains unanswered. 
We are also uncertain as to whether ANAs are produced 
as the treponemal infection progresses, for example, in 
some genetically predisposed individuals, leading then to 
host tissues damage and to induction of nontreponemal 
antibodies production. 
One of the important findings in our study was the 
detection of a high percentage (18.8%) of HIV co-infec-
tion in patients with syphilis who were unaware of their 
HIV status. This finding highlights the need for frequent 
HIV screening in individuals with syphilis. 
All individuals in our study who were serologically 
non-responsive at 6 months after the initial therapy re-
ceived an additional dose of benzathine penicillin. Of 
these patients, 83.3% still failed to have an appropri-
ate serological response 6 months after retreatment 
(12 months after initial therapy). These findings suggest 
that persistent nontreponemal antibody titers may not 
be due to the insufficient therapy, but rather an alterna-
tive process like the immune response to the treponemal 
infection. It also implies that retreatment of serological 
non-responders does not lead to improved outcomes. 
Our study has some limitations. Given the small 
sample size of this study and patients only with second-
ary syphilis and ELS included, we acknowledge that our 
data need to be interpreted with caution. Secondly, we 
showed that immune response to T. pallidum in serofast 
patients seems to be down-regulated with respect to re-
activity to TpN47. However, the mechanism underlying 
this observation remains unclear. Further studies devoted 
to determining host factors that can lead to this down-
regulation are needed. Thirdly, we assessed the presence 
of anti-nuclear antibodies after syphilis treatment in all 
included patients. Thus, we are unsure whether ANA ap-
pearance is a consequence of the spirochetal infection or 
they were present before the infection. 
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Conclusions
Our data support the hypothesis that the baseline 
antigen-specific immune response to the treponemal 
infection may be an important predictor of the treat-
ment outcome. Some autoimmune reactions, not well 
characterized until now, may also be involved in the 
pathomechanism of the serofast state. Further studies 
on larger groups are needed in order to confirm our ob-
servations and evaluate the role of the immune system 
in these findings.
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